KANABO GROUP PLC Logo

KANABO GROUP PLC

Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.

KNB | IL

Overview

Corporate Details

ISIN(s):
GB00BYQCS703
LEI:
213800XPJFSNWJIYKN52
Country:
United Kingdom
Address:
Churchill House, NW4 4DJ London
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kanabo Group PLC is a medical cannabis and wellness company that develops and distributes cannabis-derived products. The company operates a holistic business model, overseeing the entire product lifecycle from research and development to distribution. Its portfolio includes proprietary THC-based medical formulas targeting conditions like CNS disorders, alongside non-THC CBD products for the consumer wellness market. A key innovation is the VapePod®, a medically certified vaporization device designed for precise, metered-dose delivery of cannabis extracts. Kanabo focuses on creating clinically validated, high-quality formulations and has expanded its offerings to include a digital health platform providing patient access to alternative therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-04 08:00
Business and Financial Review
Revenue Growth, Trading and Operational Update
English 19.6 KB
2025-01-06 08:00
Board/Management Information
Directorate Change
English 11.3 KB
2024-11-19 10:55
Report Publication Announcement
The GP Service Wins Award
English 9.2 KB
2024-10-31 10:48
Director's Dealing
Correction Director/PDMR Shareholding
English 27.2 KB
2024-10-29 12:39
Director's Dealing
Director/PDMR Shareholding
English 26.7 KB
2024-09-30 15:50
Earnings Release
Half-year Report
English 307.5 KB
2024-08-28 15:31
Director's Dealing
Director/PDMR Shareholding
English 35.2 KB
2024-06-27 17:49
Declaration of Voting Results & Voting Rights Announcements
Result of AGM
English 23.0 KB
2024-06-04 08:00
Regulatory News Service
Expansion:14 New Clinics Partnership with Treat-It
English 16.6 KB
2024-05-31 11:30
Pre-Annual General Meeting Information
Notice of AGM
English 12.0 KB
2024-04-30 15:15
Annual Report
Annual Financial Report
English 895.4 KB
2024-03-28 08:00
Business and Financial Review
Expansion of Treat It to Mental Health Treatments
English 14.0 KB
2024-03-27 18:11
Major Shareholding Notification
Holding(s) in Company
English 24.2 KB
2024-03-25 08:00
Legal Proceedings Report
Germany Medical Cannabis Legislation Reform
English 14.0 KB
2024-03-18 10:14
Regulatory News Service
Agritec Update
English 13.9 KB

Automate Your Workflow. Get a real-time feed of all KANABO GROUP PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KANABO GROUP PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KANABO GROUP PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.